Yagara
Yagara Price range: $ 25,00 through $ 69,00
Back to products
Zytanix
Zytanix Price range: $ 19,00 through $ 51,00

Yaz

Price range: $ 15,00 through $ 40,00

Yaz is a combined oral contraceptive pill formulated to effectively prevent pregnancy when taken daily as directed. Each tablet contains a blend of two hormones, drospirenone and ethinyl estradiol, which work together to regulate the reproductive cycle. Beyond contraception, this medication is FDA-approved for the treatment of moderate acne in women seeking a hormonal approach to clearer skin. It is also a recognized option for managing the physical and emotional symptoms associated with Premenstrual Dysphoric Disorder (PMDD). The convenient 28-day regimen helps maintain consistent hormone levels to support reproductive health and symptom management.

Active substance: drospirenone, ethinylestradiol
SKU: Yaz Categories: ,
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Yaz – Information for Patients and Caregivers

Yaz belongs to a class of combined oral contraceptives containing an estrogen (ethinyl estradiol) and a progestin (drospirenone). As a prescription-only drug regulated by the U.S. Food and Drug Administration (FDA), it is indicated for oral administration to prevent pregnancy and manage specific endocrine-responsive conditions in females. Optimal therapeutic outcomes rely on strict adherence to the prescribed daily regimen and clinical monitoring by a qualified healthcare provider.

This reference overview details the pharmacological characteristics, dosing schedules, potential adverse events, and critical safety considerations associated with Yaz. Patients prescribed this medication should review all clinical precautions and maintain regular communication with their physician.

Basic Information

Active Ingredients Drospirenone (3 mg) / Ethinyl estradiol (0.02 mg)
Therapeutic Class Combination Oral Contraceptive (Estrogen and Progestin)
Dosage Form Oral tablet (24 active light pink tablets, 4 inert white tablets)
Route of Administration Oral
Primary Purpose Contraception, PMDD symptom management, moderate acne treatment
Prescription Status Prescription (Rx) only

Main Uses

Yaz is indicated primarily for the prevention of pregnancy in females who elect to use an oral contraceptive. In addition, the FDA has approved this drug for the treatment of symptoms associated with premenstrual dysphoric disorder (PMDD) in women who choose an oral contraceptive for birth control. The efficacy of Yaz for PMDD when used for more than three menstrual cycles has not been established in long-term clinical trials. Yaz is also indicated for the treatment of moderate acne vulgaris in females at least 14 years of age who have reached menarche, have no known contraindications to oral contraceptive therapy, and desire an oral contraceptive for birth control. Uses outside these primary FDA-approved indications represent off-label prescribing and must be clinically evaluated by a healthcare provider on an individual patient basis.

How the Drug Works

The mechanism of action of Yaz relies on the synergistic pharmacological activities of ethinyl estradiol and drospirenone. Combination oral contraceptives suppress gonadotropins, inhibiting the pituitary release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). This primary activity prevents follicular development and suppresses ovulation during the menstrual cycle. Secondary mechanisms include alterations in cervical mucus viscosity, which hinders sperm penetration into the uterine cavity, and structural changes in the endometrium that reduce the likelihood of blastocyst implantation. Drospirenone is a spironolactone analog that exhibits antimineralocorticoid and antiandrogenic properties, which contribute to its therapeutic activity in managing acne and fluid-retention symptoms of PMDD.

What Happens in the Body

Following oral administration, both active components of Yaz undergo rapid absorption. Drospirenone exhibits a mean absolute bioavailability of approximately 76%, achieving peak plasma concentrations within 1 to 2 hours post-dose. Ethinyl estradiol reaches peak serum levels within 1 to 2 hours. Drospirenone binds to serum albumin but does not bind to sex hormone-binding globulin (SHBG) or corticosteroid-binding globulin (CBG). Conversely, ethinyl estradiol binds heavily to serum albumin and induces SHBG synthesis. Drospirenone undergoes extensive hepatic metabolism into inactive metabolites. Its terminal elimination half-life is approximately 30 hours. Ethinyl estradiol is metabolized predominantly by hepatic cytochrome P450 enzymes (CYP3A4) and eliminated via urine and feces with a half-life of roughly 24 hours.

Dosing Schedule

Yaz is supplied in a 28-day blister package containing 24 light pink active tablets (each containing 3 mg drospirenone and 0.02 mg ethinyl estradiol) and 4 white inert placebo tablets. Patients must take one tablet daily by mouth at the same time each day to maintain stable plasma steroid concentrations. Pill intake must follow the sequential order marked on the package. Withdrawal bleeding typically occurs during the 4-day placebo phase. Contraceptive protection requires unbroken daily administration; a new 28-day blister pack must be initiated on the day immediately following the last white inert tablet, regardless of whether withdrawal bleeding has ceased.

If You Skip a Dose

Missing active tablets reduces contraceptive efficacy and increases the probability of breakthrough bleeding or ovulation. If one light pink active tablet is missed, the patient should take the missed tablet as soon as remembered and take the next tablet at the regular scheduled time. If two active tablets are missed consecutively in Weeks 1 or 2, the patient should take two tablets on the day remembered and two on the following day, while utilizing a non-hormonal back-up contraceptive method (such as condoms) for 7 consecutive days. Precise missed-pill instructions vary depending on the timing within the cycle and whether a Sunday Start or Day 1 Start was initiated.

Compatibility with Other Medicines

Concomitant administration of Yaz with hepatic enzyme-inducing agents can significantly reduce contraceptive efficacy and increase breakthrough bleeding. Substances such as rifampin, carbamazepine, phenytoin, phenobarbital, topiramate, and St. John’s wort induce CYP3A4 metabolism, accelerating the clearance of active steroids. When co-administering enzyme inducers, non-hormonal back-up contraception is required. Additionally, because drospirenone exhibits antimineralocorticoid activity, concomitant use of agents that elevate serum potassium–including ACE inhibitors, angiotensin receptor blockers (ARBs), potassium-sparing diuretics, potassium supplements, and chronic NSAID therapy–warrants baseline serum potassium assessment during the first cycle of treatment.

What to Avoid While Taking It

Yaz may be taken without regard to meals. Alcohol consumption does not directly alter the metabolic clearance of drospirenone or ethinyl estradiol, but heavy alcohol consumption can impair hepatic function, potentially altering drug metabolism and patient compliance. Patients should avoid salt substitutes containing potassium chloride and high-dose potassium supplements without consulting their physician, as drospirenone’s aldosterone antagonist activity can promote potassium retention in vulnerable individuals.

What Side Effects May Occur

Common adverse reactions associated with Yaz include headache, intermenstrual spotty bleeding, dysmenorrhea, nausea, breast pain or tenderness, mood alterations, and fatigue. Less frequent but severe adverse events include arterial thromboembolism, venous thromboembolism (DVT and pulmonary embolism), hypertension, gallbladder disease, hyperkalemia, and benign or malignant hepatic adenomas. Epidemiological studies demonstrate that drospirenone-containing oral contraceptives carry a higher relative risk of venous thromboembolism compared to combined oral contraceptives containing progestins such as levonorgestrel. Patients experiencing persistent or severe side effects should contact their healthcare provider.

Red Flags

Clinical Symptom Potential Underlying Risk
Severe chest pain or shortness of breath Pulmonary embolism or myocardial infarction
Severe unilateral leg pain or lower limb edema Deep vein thrombosis (DVT)
Sudden severe headache or visual disturbances Cerebrovascular accident (stroke) or retinal thrombosis
Persistent severe right upper quadrant abdominal pain Hepatic adenoma or gallbladder disease
Jaundice (yellowing of skin or sclera) Hepatic dysfunction or cholestasis

Immediate medical evaluation is mandatory if any acute red flag symptoms develop during therapy. Manifestations such as sudden chest pain, dyspnea, hemoptysis, unilateral leg swelling, sudden loss of vision, or severe headache indicate severe cardiovascular, thromboembolic, or hepatic complications. Patients presenting with these signs must seek emergency medical intervention immediately.

Important Precautions

Cigarette smoking significantly increases the risk of serious cardiovascular adverse events in women taking combination oral contraceptives. This risk increases markedly with age (particularly in women over 35 years of age) and with heavy smoking (15 or more cigarettes per day). Yaz is strictly contraindicated in women over 35 who smoke. Additional contraindications include a history of deep vein thrombosis, pulmonary embolism, cerebrovascular disease, coronary artery disease, severe hepatic impairment, renal impairment, adrenal insufficiency, undiagnosed abnormal uterine bleeding, and known or suspected estrogen-dependent neoplasia such as breast cancer. Baseline blood pressure evaluation is required prior to initiation.

Special Populations

Yaz is contraindicated during pregnancy. If pregnancy occurs during administration, the medication must be discontinued immediately. Combined oral contraceptives can reduce breast milk production and alter milk composition in lactating mothers; estrogens and progestins are excreted in human milk. Alternative contraceptive methods are recommended until complete weaning. Yaz is indicated only in females who have achieved menarche; safety and efficacy have not been established in pediatric populations prior to puberty. Yaz is not indicated for postmenopausal women.

Common Questions

How does drospirenone differ from other progestins used in birth control pills?

Drospirenone is a synthetic progestin derived from 17-alpha-spironolactone. Unlike older progestins derived from 19-nortestosterone, drospirenone possesses antimineralocorticoid and antiandrogenic properties. This pharmacological profile mimics natural progesterone more closely, assisting in the control of water retention and androgenic symptoms such as acne, though it requires attention to potassium balance in susceptible patients.

Is serum potassium monitoring necessary while taking Yaz?

Potassium monitoring is not routinely required for healthy individuals taking Yaz. However, patients with conditions predisposing to hyperkalemia, or those taking concurrent medications that elevate serum potassium (such as ACE inhibitors, ARBs, or daily NSAID therapy), must have their serum potassium concentration evaluated during the first treatment cycle to ensure safety.

What should be done if vomiting or severe diarrhea occurs shortly after taking a tablet?

If severe vomiting or diarrhea occurs within 3 to 4 hours of taking a light pink active tablet, absorption may be incomplete. This scenario is managed as a missed tablet. The patient should follow the missed-pill guidelines specified in the FDA label and utilize a non-hormonal back-up contraceptive method until gastrointestinal symptoms resolve and continuous tablet intake is restored for 7 consecutive days.

Can Yaz cause changes in blood pressure?

Combination oral contraceptives, including Yaz, can cause an elevation in blood pressure in some patients. In women with controlled hypertension, blood pressure must be monitored regularly during therapy. If significant or sustained blood pressure elevations occur, discontinuation of the medication and transitioning to an alternative contraceptive method may be clinically indicated.

How long does it take for contraceptive protection to become effective?

If Yaz is initiated on Day 1 of the menstrual cycle (Day 1 Start), contraceptive protection is immediate. If therapy is initiated on the first Sunday following the onset of menses (Sunday Start), a non-hormonal back-up contraceptive method, such as condoms, must be used concurrently for the first 7 consecutive days of tablet administration.

In accordance with FDA regulatory guidelines, the information presented here is for reference only and does not substitute for clinical judgment.

Disclaimer: Always consult your healthcare provider before starting or changing any treatment.

Additional information
Dosage

0.02 mg + 3 mg

Package

28 tabs

,

56 tabs

,

84 tabs

Ενεργός Ουσία

,